$ANIP Cashflow Statement | Understand Stock

$ANIP

$72.60 -$0.01 (0.01%) Close

$ANIP Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash Flows From Operating Activities
Net income (loss)
Adjustments to reconcile net income (loss) to net cash and cash equivalents provided by operating activities:
Stock-based compensation
Deferred taxes
Depreciation and amortization
Unrealized gain on investment in equity securities
Acquired in-process research and development ("IPR&D")
Non-cash operating lease expense
Non-cash interest
Contingent consideration fair value adjustment
Loss (gain) on disposal of assets
Loss on extinguishment of debt
Amortization of inventory step up
Asset impairment charges
Gain on sale of ANDAs
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable, net
Inventories
Prepaid expenses and other assets
Accounts payable
Accrued royalties
Income taxes
Accrued government rebates
Returned goods reserve
Accrued expenses, accrued compensation, and other
Net Cash and Cash Equivalents Provided by Operating Activities
Cash Flows From Investing Activities
Acquisition of Alimera, net of cash acquired
Alimera
Novitium Pharma LLC
Total acquisition of Alimera, net of cash acquired
Acquisition of product rights, intangible assets, and other related assets
Acquisition of property and equipment, net
Proceeds from the sale of long-lived assets
Proceeds from the sale of building
Net Cash and Cash Equivalents Used in Investing Activities
Cash Flows From Financing Activities
Proceeds from convertible notes
Proceeds from term loan
Purchase of capped call transaction
Proceeds from public offering
Cash paid for costs of share issuances
Payments on contingent consideration
Principal payments on borrowings
Borrowings under Delayed Draw Term Loan agreement
Payments on borrowings under credit agreements
Payments on Revolver agreement
Debt issuance costs
Repayment on borrowings under credit agreement
Borrowings under the Credit Facility, net of issuance costs
Proceeds from issuance of convertible preferred stock
Payment of accrued licensor payment
Series A convertible preferred stock dividends paid
Proceeds from stock option exercises and ESPP purchases
Repayment of Convertible Notes
Treasury stock purchases for restricted stock vests
Net Cash and Cash Equivalents (Used in) Provided by Financing Activities

Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash
Net Change in Cash, Cash Equivalents, and Restricted Cash
Cash and cash equivalents, beginning of year
Cash, cash equivalents and restricted cash, end of year
Cash and cash equivalents
Restricted cash
Supplemental disclosure for cash flow information:
Cash paid for interest, net of amounts capitalized
Cash paid for income taxes, net of refunds received
Right-of-use assets obtained in exchange for lease obligations
Supplemental non-cash investing and financing activities:
Fair value of contingent consideration in a business combination
Purchase consideration for acquisition of Alimera
Fair value of equity issued as consideration in a business combination
Acquisition of product rights, IPR&D, and other related assets included in returned goods reserve and derivatives and other non-current liabilities
Acquisition of product rights included in accounts payable
Conversion of convertible preferred stock into common stock
Property and equipment purchased and included in accounts payable

Reconciliation of cash, cash equivalents, and restricted cash, beginning of year
Cash and cash equivalents
Restricted cash

Comments